84 related articles for article (PubMed ID: 18989348)
1. Sustained moderate visual loss as a predictive end point for visual loss in non-proliferative diabetic retinopathy.
Girach A; Aiello LP; Milton RC; Davis MD; Danis RP; Zhi X; Sheetz MJ; Vignati L;
Eye (Lond); 2009 Jan; 23(1):209-14. PubMed ID: 18989348
[TBL] [Abstract][Full Text] [Related]
2. Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2).
Sheetz MJ; Aiello LP; Shahri N; Davis MD; Kles KA; Danis RP;
Retina; 2011 Jun; 31(6):1053-9. PubMed ID: 21386766
[TBL] [Abstract][Full Text] [Related]
3. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.
; Aiello LP; Davis MD; Girach A; Kles KA; Milton RC; Sheetz MJ; Vignati L; Zhi XE
Ophthalmology; 2006 Dec; 113(12):2221-30. PubMed ID: 16989901
[TBL] [Abstract][Full Text] [Related]
4. Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2.
Aiello LP; Vignati L; Sheetz MJ; Zhi X; Girach A; Davis MD; Wolka AM; Shahri N; Milton RC;
Retina; 2011 Nov; 31(10):2084-94. PubMed ID: 21862954
[TBL] [Abstract][Full Text] [Related]
5. The effect of the oral PKC β inhibitor ruboxistaurin on vision loss in two phase 3 studies.
Sheetz MJ; Aiello LP; Davis MD; Danis R; Bek T; Cunha-Vaz J; Shahri N; Berg PH;
Invest Ophthalmol Vis Sci; 2013 Mar; 54(3):1750-7. PubMed ID: 23404115
[TBL] [Abstract][Full Text] [Related]
6. Diabetic macular oedema and visual loss: relationship to location, severity and duration.
Gardner TW; Larsen M; Girach A; Zhi X;
Acta Ophthalmol; 2009 Nov; 87(7):709-13. PubMed ID: 19817721
[TBL] [Abstract][Full Text] [Related]
7. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial.
PKC-DRS Study Group
Diabetes; 2005 Jul; 54(7):2188-97. PubMed ID: 15983221
[TBL] [Abstract][Full Text] [Related]
8. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.
Davis MD; Sheetz MJ; Aiello LP; Milton RC; Danis RP; Zhi X; Girach A; Jimenez MC; Vignati L;
Invest Ophthalmol Vis Sci; 2009 Jan; 50(1):1-4. PubMed ID: 18708615
[TBL] [Abstract][Full Text] [Related]
9. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.
Sahu AK; Majji AB
Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6890; author reply 6890-1. PubMed ID: 21123772
[No Abstract] [Full Text] [Related]
10. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy.
Casellini CM; Barlow PM; Rice AL; Casey M; Simmons K; Pittenger G; Bastyr EJ; Wolka AM; Vinik AI
Diabetes Care; 2007 Apr; 30(4):896-902. PubMed ID: 17392551
[TBL] [Abstract][Full Text] [Related]
11. Ruboxistaurin: LY 333531.
Drugs R D; 2007; 8(3):193-9. PubMed ID: 17472415
[TBL] [Abstract][Full Text] [Related]
12. The longitudinal link between visual acuity and health-related quality of life in patients with diabetic retinopathy.
Matza LS; Rousculp MD; Malley K; Boye KS; Oglesby A
Health Qual Life Outcomes; 2008 Nov; 6():95. PubMed ID: 18992161
[TBL] [Abstract][Full Text] [Related]
13. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.
Joy SV; Scates AC; Bearelly S; Dar M; Taulien CA; Goebel JA; Cooney MJ
Ann Pharmacother; 2005 Oct; 39(10):1693-9. PubMed ID: 16160002
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy].
Emmerich KH; Poritis N; Stelmane I; Klindzane M; Erbler H; Goldsteine J; Görtelmeyer R
Klin Monbl Augenheilkd; 2009 Jul; 226(7):561-7. PubMed ID: 19644802
[TBL] [Abstract][Full Text] [Related]
15. Visual outcome of laser treatment in diabetic retinopathy.
Shrestha S; Karki DB; Byanju R; Malla OK; Shrestha SM; Pradhananga CL
Kathmandu Univ Med J (KUMJ); 2007; 5(1):72-80. PubMed ID: 18603990
[TBL] [Abstract][Full Text] [Related]
16. Complex deep lamellar endothelial keratoplasty for complex bullous keratopathy with severe vision loss.
Huang T; Wang Y; Gao N; Wang T; Ji J; Chen J
Cornea; 2009 Feb; 28(2):157-62. PubMed ID: 19158557
[TBL] [Abstract][Full Text] [Related]
17. PKC inhibition and diabetic microvascular complications.
Clarke M; Dodson PM
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):573-86. PubMed ID: 18054736
[TBL] [Abstract][Full Text] [Related]
18. Randomised controlled trial of posterior sub-Tenon triamcinolone as adjunct to panretinal photocoagulation for treatment of diabetic retinopathy.
Unoki N; Nishijima K; Kita M; Suzuma K; Watanabe D; Oh H; Kimura T; Sakamoto A; Yoshimura N
Br J Ophthalmol; 2009 Jun; 93(6):765-70. PubMed ID: 19218250
[TBL] [Abstract][Full Text] [Related]
19. Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease.
Tuttle KR; McGill JB; Haney DJ; Lin TE; Anderson PW;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):631-6. PubMed ID: 17699475
[TBL] [Abstract][Full Text] [Related]
20. Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: a literature review.
Fong DS; Girach A; Boney A
Retina; 2007 Sep; 27(7):816-24. PubMed ID: 17891003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]